Scleroderma (systemic sclerosis [SSc]) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and varying degrees of vasculopathy that manifest as Raynaud’s disease and, often, painful digital ulcers. Risks of PAH, ILD, and renal crisis are higher in SSc patients than in the general population and underlie a high mortality rate. A complex array of treatments may be used in the management of SSc; systemic immunosuppressants are prescribed to treat ILD and skin fibrosis, while other symptoms (e.g., PAH, vasculopathy, renal crisis) are treated with varying combinations of calcium-channel blockers, endothelin receptor antagonists, PDE-5 inhibitors, prostacyclin analogues, and ACE inhibitors. This content provides context for emerging players seeking to capitalize on the unmet needs in this underserved arena.
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world, patient-level claims data, so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.